Phase II trial of N-methylformamide for advanced renal cell carcinoma.
Sternberg
C N
CN
Yagoda
A
A
Scher
H I
HI
Hollander
P
P
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D056486:Chemical and Drug Induced Liver Injury; D004341:Drug Evaluation; D005260:Female; D005559:Formamides / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced
D000970:Antineoplastic Agents; D005559:Formamides; C002950:methylformamide